Publication
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerHER2-Positive Breast Carcinomacivic_curation1.00
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugTrastuzumabcivic_curation1.00
- geneERBB4civic_curation1.00
- variantERBB4 EXPRESSIONcivic_curation1.00
- variantERBB4 NUCLEAR TRANSLOCATIONcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25153719
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB4 EXPRESSION2 | ||||||||
| (prognostic) | HER2-Positive Breast CarcinomaALIAS | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID1961Preventing HER4 cleavage by a γ-secretase inhibitor and inhibiting HER4 tyrosine kinase activity by neratinib decreased trastuzumab-induced HER4 nuclear translocation and enhanced trastuzumab response… (full text at CIViC) PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC | civic |
| Trastuzumab | HER2-Positive Breast CarcinomaALIAS | Predictive | D | Supports Resistance | 2 | accepted | EID868siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines. PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC | civic |
| ERBB4 NUCLEAR TRANSLOCATION1 | ||||||||
| Trastuzumab | Malignant Breast Neoplasm | Predictive | D | Supports Resistance | 2 | accepted | EID867HER4 nuclear translocation was identified as a mediator of trastuzumab resistance in HER2 positive breast cancer cell lines. Increased nuclear staining was also identified in xenograft and patient sam… (full text at CIViC) PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC | civic |